Combination of RSK inhibitor LJH-685 and FLT3 inhibitor FF-10101 promoted apoptosis and proliferation inhibition of AML cell lines

被引：0
|
作者：
Sen Zhang
Jun Liu
Zi-Yi Lu
Yu-Tong Xue
Xing-Ru Mu
Yang Liu
Jiang Cao
Zhen-Yu Li
Feng Li
Kai-Lin Xu
Qing-Yun Wu
机构：
[1] Xuzhou Medical University,Blood Diseases Institute
[2] The Affiliated Hospital of Xuzhou Medical University,Department of Hematology
[3] Xuzhou Medical University,Department of Cell Biology and Neurobiology
来源：
Cellular Oncology | 2022年 / 45卷
关键词：
AML; RSKs; FLT3-ITD; LJH-685; FF-10101; Proliferation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1005 / 1018
页数：13
相关论文
共 20 条
  • [1] Combination of RSK inhibitor LJH-685 and FLT3 inhibitor FF-10101 promoted apoptosis and proliferation inhibition of AML cell lines
    Zhang, Sen
    Liu, Jun
    Lu, Zi-Yi
    Xue, Yu-Tong
    Mu, Xing-Ru
    Liu, Yang
    Cao, Jiang
    Li, Zhen-Yu
    Li, Feng
    Xu, Kai-Lin
    Wu, Qing-Yun
    CELLULAR ONCOLOGY, 2022, 45 (05) : 1005 - 1018
  • [2] The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms
    Ferng, Timothy T.
    Terada, Daisuke
    Ando, Makoto
    Tarver, Theodore C.
    Chaudhary, Fihr
    Lin, Kimberly C.
    Logan, Aaron C.
    Smith, Catherine C.
    MOLECULAR CANCER THERAPEUTICS, 2022, 21 (05) : 844 - 854
  • [3] The irreversible FLT3 inhibitor FF-10101 is active against a diversity of FLT3 inhibitor resistance mechanisms
    Ferng, Timothy T.
    Terada, Daisuke
    Ando, Makoto
    Tarver, Theodore C.
    Chaudhary, Fihr
    Lin, Kimberly C.
    Logan, Aaron C.
    Smith, Catherine C.
    CANCER RESEARCH, 2022, 82 (12)
  • [4] A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations
    Yamaura, Takeshi
    Nakatani, Toshiyuki
    Uda, Ken
    Ogura, Hayato
    Shin, Wigyon
    Kurokawa, Naoya
    Saito, Koichi
    Fujikawa, Norie
    Date, Tomomi
    Takasaki, Masaru
    Terada, Daisuke
    Hirai, Atsushi
    Akashi, Akimi
    Chen, Fangli
    Adachi, Yoshiya
    Ishikawa, Yuichi
    Hayakawa, Fumihiko
    Hagiwara, Shinji
    Naoe, Tomoki
    Kiyoi, Hitoshi
    BLOOD, 2018, 131 (04) : 426 - 438
  • [5] The Novel, Irreversible FLT3 Inhibitor FF-10101 Demonstrates Broad in Vitro Activity Against FLT3 Inhibitor Resistance Mutations
    Ferng, Timothy T.
    Tarver, Theodore C., III
    Smith, Catherine C.
    BLOOD, 2017, 130
  • [6] Discovery of a novel irreversible and potent FLT3 inhibitor FF-10101 under clinical investigation
    Takasaki, Masaru
    Hirai, Atsushi
    Terada, Daisuke
    Okubo, Megumi
    Tsujino, Toshiaki
    Sato, Kimihiko
    Tanabe, Shintaro
    Inuki, Shinsuke
    Mizumoto, Shinsuke
    Fujikawa, Norie
    Hirano, Daisuke
    Yamaura, Takeshi
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 253
  • [7] Combination of bortezomib with a FLT3 inhibitor potentiates inhibition of proliferation and apoptosis of AML in vitro
    Cheng, P. C.
    Crane, J.
    Hunter, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] Development of FF-10101, a Novel Irreversible FLT3 Inhibitor, Which Overcomes Drug Resistance Mutations
    Nakatani, Toshiyuki
    Uda, Ken
    Yamaura, Takeshi
    Takasaki, Masaru
    Akashi, Akimi
    Chen, Fangli
    Ishikawa, Yuichi
    Hayakawa, Fumihiko
    Hagiwara, Shinji
    Kiyoi, Hitoshi
    Naoe, Tomoki
    BLOOD, 2015, 126 (23)
  • [9] A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia
    Levis, Mark
    Perl, Alexander
    Schiller, Gary
    Fathi, Amir T.
    Roboz, Gail
    Wang, Eunice S.
    Altman, Jessica
    Rajkhowa, Trivikram
    Ando, Makoto
    Suzuki, Takeaki
    Subach, Ruth Ann
    Maier, Gary
    Madden, Timothy
    Johansen, Mary
    Cheung, Kin
    Kurman, Michael
    Smith, Catherine
    BLOOD ADVANCES, 2024, 8 (10) : 2527 - 2535
  • [10] Characterization of a novel FLT3 inhibitor in AML cell lines
    Wall, Hayley S.
    Bao Nguyen
    Greenblatt, Sarah
    Small, Donald
    CANCER RESEARCH, 2012, 72
12